Principal Side Effect of Ganciclovir Therapy

Mechanism and Severity of Bone Marrow Suppression

The Centers for Disease Control and Prevention recommends that myelosuppression is the major dose-limiting toxicity of ganciclovir, requiring dose reduction or interruption in up to 40% of patients due to hematologic toxicity 1, 2
Severe neutropenia may necessitate treatment with granulocyte colony-stimulating factor to ameliorate marrow suppression 3, 1
In a phase III trial of ganciclovir treatment for congenital CMV infection, approximately two-thirds of infants experienced substantial neutropenia during therapy 3

The Centers for Disease Control and Prevention suggests that dose reduction or complete interruption of therapy might be necessary in patients experiencing significant myelosuppression 1, 4
Regular monitoring of complete blood counts is essential during ganciclovir therapy, with recommended frequency of twice weekly during induction therapy and once weekly during maintenance 5, 4

Renal toxicity, manifested as increased serum creatinine, which may require dose modification 1, 5
Elevated liver enzymes, though these occur less frequently than bone marrow suppression 3, 1
Thrombophlebitis at the site of intravenous administration 1

Complete blood counts should be monitored twice weekly during induction therapy and once weekly during maintenance therapy 4, 2
Renal function should be monitored regularly as renal toxicity can occur and may require dose adjustment 5, 2

Foscarnet may be considered as an alternative to ganciclovir in patients who cannot tolerate ganciclovir due to severe bone marrow suppression, though it has significant nephrotoxicity 6, 5

Patients with HIV/AIDS and transplant recipients face additional risks of neutropenia and thrombocytopenia, which can overlap with manifestations of systemic CMV, and a multidisciplinary approach including infectious disease specialists is recommended for managing severe hematologic toxicity 7
Foscarnet may be considered as an alternative in patients who cannot tolerate ganciclovir due to severe bone marrow suppression, but it has significant nephrotoxicity and requires careful management 7

Clinical guidelines do not list serum calcium measurement as part of routine toxicity monitoring for patients receiving ganciclovir, indicating that calcium monitoring is not required in standard surveillance protocols. 8, 9, 10

The MMWR Recommendations advise that ganciclovir should be stopped immediately when cytopenias develop, holding the drug until blood counts recover to safe thresholds before resuming at reduced doses or switching to foscarnet if the cytopenias are severe or recurrent. 11
According to the National Comprehensive Cancer Network (NCCN), the drug should be held for grade 3‑4 neutropenia (ANC < 1,000 cells/µL) until the absolute neutrophil count reaches ≥ 1,500 cells/µL; for grade 3‑4 thrombocytopenia (platelets < 50,000 µL) until platelets reach ≥ 75,000 µL. 12

The MMWR Recommendations require complete blood count (CBC) monitoring twice weekly during induction therapy and at least once weekly during maintenance to detect emerging cytopenias promptly. 11
The MMWR Recommendations also call for electrolyte monitoring at least twice weekly, noting that hypocalcemia, hypophosphatemia, and hypomagnesemia occur in roughly 33 % of patients receiving foscarnet. 11

The NCCN recommends that if the ANC recovers to ≥ 1,500 cells/µL within 2 weeks, ganciclovir may be resumed at the original dose (5 mg/kg IV twice daily). 12
If cytopenia recurs after resumption, the NCCN advises reducing the dose to 3 mg/kg IV twice daily or switching to an alternative antiviral. 12
When platelet counts recover to ≥ 75,000 µL within 2 weeks, the original ganciclovir dose may be reinstated; if thrombocytopenia recurs, dose reduction or discontinuation is recommended. 12
If hematologic recovery requires more than 2 weeks, the NCCN suggests restarting ganciclovir at a 25‑33 % dose reduction and considering alternative therapy. 12

The NCCN supports the use of granulocyte colony‑stimulating factor (G‑CSF) in combination with ganciclovir for patients with neutropenia that is resistant to dose adjustment. 12
The Blood Cancer Journal cautions that G‑CSF should be avoided during periods when the patient is at risk for cytokine‑release syndrome. 13

The MMWR Recommendations state that clinicians should switch to foscarnet when patients experience severe or recurrent dose‑limiting neutropenia or thrombocytopenia despite ganciclovir dose modifications. 11

The NCCN warns against continuing ganciclovir at full dose when early cytopenias appear (ANC 1,000‑1,500 cells/µL or platelets 50,000‑75,000 µL); instead, proactive dose reduction or intensified monitoring is required. 12